Horizon Discovery CEO Darrin Disley has scooped another major accolade after being named Entrepreneur of the Year at last night’s Quoted Company Awards 2014 in London.
AstraZeneca, which is building its bulk in the Cambridge UK life science cluster, is harnessing the power of bleeding edge gene editing technology to boost future drug development.
Data management software from CRedit360 in Cambridge UK has been bought by global chemical and pharmaceutical heavyweight Merck to help improve the consistency of its global sustainability data management and reporting.
Pivotal trials using Cambridge UK medical technology to fight breast cancer are underway at six sites across the United States.
Dr Geraldine Rodgers, a founding director, seed investor and non-executive director in Cambridge gene editing company Horizon Discovery and former head of seed funds for the university’s commerialisation arm, Cambridge Enterprise, has died after a long battle with lung cancer. She was 66.
Diagnostic technology specialist Sphere Medical has revealed a surge in sales prospects for its new device Proxima 3 from potential customers in the UK and Europe as it builds commercial capability.
In describing the current activities and dynamics of this part of the UK one needs to consider not just the immensely exciting growth of the Cambridge Cluster but also how the M11 is shaping up to be a cash flow highway for our high growth life science companies.
Cambridge is to host a biotech summit for life science executives to meet New Jersey Governor Chris Christie on his visit to the UK in early February.
Abcam, the Cambridge UK life science tools supplier, has agreed to pay $28 million cash for a US company commercialising technology developed at MIT.
The Cambridge medical technology cluster is leading an upsurge of VC investment into UK biotech.
The relentless rise of Cambridge personalised medicines pioneer Horizon Discovery was re-emphasised today when the company revealed it was sitting on an R & D milestones and product royalties gold mine in a trading update to the UK market.
Bristol-Myers Squibb has initiated a Phase 1 trial in the US of Cambridge UK company F-star’s lead compound – FS102 – to treat HER2-positive breast and gastric cancer.
Fluidic Analytics Limited, a technology spinout from the UK‘s University of Cambridge, has raised £1.56 million ($2.4 million) in a Series A financing led by Cambridge Enterprise and including DFJ Esprit, IQ Capital, Parkwalk Advisors and Amadeus Capital Partners as co-investors.
UroSens, a Cambridge UK company developing novel, non-invasive urine tests for the detection of prostate and bladder cancer, has received £2 million ($3.02 million) investment to commercialise the diagnostic technology.
New drugs to fight cancer, but with greater efficacy and less side effects, are to be developed by a global expert in the disease working with a Cambridge UK antibody technology company.
Abzena subsidiary Antitope – based in the Cambridge UK medical technology heartland – is collaborating with major organisations in France and the US in a programme key to the development of two novel HIV vaccines.
- Abcam unlocks opportunity with Singapore collaboration
- Horizon boosts world gene editing lead with £10m acquisition
- Vectura clinches multi-million dollar Janssen deal
- Cambridge skin cancer app turns up the heat at CES
- United States grants Heptares multiple patents
- Significant deal ends blockbusting year for Horizon
- Cannabis-based company joins NASDAQ bio index
- US support for Cambridge Ebola technology
- Massive demand for top medical device developers
- Medical smartwatch targets $2bn market
- Crescendo raises further funding
- Genomics powerhouse spins out of Sanger in £12.5m launch
- Cambridge move gives Abzena springboard to global growth
- Procter & Gamble turns to Eagle for bioinformatics software
- Horizon taps £2.9bn large molecule market
- Clinical trials boost via Linguamatics-Thomson Reuters alliance
Page 1 of 69